Anesthesia Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Med Sci. 2022 Jan;47(1):25-32. doi: 10.30476/ijms.2020.84509.1471.
Emergence Agitation (EA) is a dissociated state of consciousness characterized by irritability, uncompromising stance, and inconsolability. The etiology of EA is not completely understood. Dexmedetomidine is a highly selective α-adrenoreceptor agonist with sedative and analgesic properties, which has been used to reduce the incidence of EA. We aimed to assess the efficacy of early versus late administration of dexmedetomidine on EA in children undergoing oral surgery.
A randomized, parallel, double-blind clinical trial was conducted at Mofid Children's Hospital affiliated to Shahid Beheshti University of Medical Sciences (Tehran, Iran) from November 2016 to March 2017. A total of 81 children, who underwent adenotonsillectomy or cleft palate repair surgery were enrolled in the study. Based on simple randomization, the children were assigned to two groups, namely early (group A, n=41) and late (group B, n=40) administration of dexmedetomidine. Intra-operative and postoperative hemodynamic variables, extubation time, post-anesthesia care unit (PACU) length of stay, and the scores on Ramsay sedation scale and FLACC pain scale were measured and compared. The data were analyzed using SPSS software (version 20.0), and P<0.05 were considered statistically significant.
The mean FLACC score was lower in the late group than in the early group (2.0±1.5 vs. 4.2±1.6, P<0.001). The mean Ramsay sedation score was higher in the late group than in the early group (3.5±1.4 vs. 1.8±0.8, P<0.001).
Late administration of dexmedetomidine 1 µg/kg reduced the incidence of EA and PACU length of stay and improved postoperative pain management.
IRCT 2016122031497N1.
苏醒期躁动(EA)是一种意识分离状态,其特征为易怒、不妥协和无法安慰。EA 的病因尚未完全阐明。右美托咪定是一种高度选择性的α-肾上腺素受体激动剂,具有镇静和镇痛作用,已被用于降低 EA 的发生率。我们旨在评估口腔手术患儿中早期与晚期给予右美托咪定对 EA 的疗效。
一项随机、平行、双盲临床试验于 2016 年 11 月至 2017 年 3 月在德黑兰谢哈迪贝赫什提大学医学科学莫菲德儿童医院(伊朗)进行。共有 81 例接受腺样体扁桃体切除术或腭裂修复术的患儿纳入研究。根据简单随机化,患儿被分为两组,即早期(A 组,n=41)和晚期(B 组,n=40)给予右美托咪定。测量并比较术中及术后血流动力学变量、拔管时间、麻醉后监护病房(PACU)停留时间以及 Ramsay 镇静评分和 FLACC 疼痛评分。数据使用 SPSS 软件(版本 20.0)进行分析,P<0.05 为统计学显著差异。
晚期组的平均 FLACC 评分低于早期组(2.0±1.5 与 4.2±1.6,P<0.001)。晚期组的平均 Ramsay 镇静评分高于早期组(3.5±1.4 与 1.8±0.8,P<0.001)。
晚期给予 1μg/kg 右美托咪定可降低 EA 发生率和 PACU 停留时间,并改善术后疼痛管理。
IRCT 2016122031497N1。